Powering the Possible to fight pediatric cancer - New York, November 10, 2011
Neuroblastoma is one of the deadliest pediatric cancer. With little commercially or federally funded research underway because of its small patient base, parents and pediatric oncologists have relied largely on “trial and error” in their search for a treatment that will work from among the hundreds of available adult cancer trials.
To overcome these challenges, parents and physicians and scientists from the NMTRC, the Van Andel Research Institute (VARI) and TGen have teamed to launch the world’s first personalized medicine clinical trial investigation for pediatric cancer.
Dell is committed to providing the IT infrastructure, corporate funding and employee volunteers to support this trial and expand the reach to hundreds children in the future. To learn more : www.dell.com/HealthPress.
14 photos · 471 views